Dimensional Fund Advisors LP Buys 50,331 Shares of Repligen Corporation $RGEN

Dimensional Fund Advisors LP boosted its position in Repligen Corporation (NASDAQ:RGEN) by 6.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 854,741 shares of the biotechnology company’s stock after acquiring an additional 50,331 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Repligen were worth $100,681,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in RGEN. Massachusetts Financial Services Co. MA bought a new position in Repligen in the fourth quarter valued at about $199,176,000. M&T Bank Corp acquired a new stake in shares of Repligen during the fourth quarter valued at about $29,819,000. Swedbank AB bought a new stake in shares of Repligen during the fourth quarter worth about $4,146,000. Conestoga Capital Advisors LLC grew its holdings in shares of Repligen by 10.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after purchasing an additional 101,062 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in shares of Repligen in the fourth quarter valued at approximately $20,253,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Down 2.8%

Repligen stock opened at $141.23 on Thursday. The company has a quick ratio of 7.78, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The firm’s fifty day moving average is $133.54 and its 200 day moving average is $131.70. The company has a market capitalization of $7.97 billion, a PE ratio of 193.47, a PEG ratio of 2.80 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the previous year, the business earned $0.26 EPS. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Repligen News Summary

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q2 beat expectations: Repligen reported revenue of $204.1 million, up 11.9% year over year and above the $201.6 million consensus estimate. Adjusted EPS was $0.54, surpassing expectations of approximately $0.45 and rising from $0.37 a year earlier. Repligen Beats Q2 Earnings Estimates, Raises 2026 View
• Positive Sentiment: Guidance raised: Management increased its FY2026 organic revenue-growth outlook to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09, above the roughly $2.00 analyst consensus. Total reported revenue is expected to reach $813 million-$835 million. Repligen Q2 Financial Results and Updated Guidance
• Positive Sentiment: Improving operating performance: Organic growth reached 13%, while adjusted operating income rose 55% and adjusted operating margin expanded to 16.7% from 12.0%. Management cited continued order momentum and better visibility into the second half. Repligen Jumps After Q2 Beat and Higher Outlook
• Positive Sentiment: Acquisition catalyst: The planned acquisition of BioLife Solutions is expected to strengthen Repligen’s cell-therapy presence and potentially add recurring revenue, margin expansion and adjusted-EPS accretion. JPMorgan raised its price target from $165 to $175 and maintained an Overweight rating. JPMorgan Raises Repligen Price Target

Analysts Set New Price Targets

RGEN has been the topic of several analyst reports. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. Canaccord Genuity Group cut their target price on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Evercore reiterated an “outperform” rating and issued a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. Finally, HSBC decreased their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.07.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.